BA3011 (CAB-AXL-ADC)
Advanced Solid Tumors (e.g., Sarcoma, NSCLC)
Phase 2Active (as of last update)
Key Facts
Indication
Advanced Solid Tumors (e.g., Sarcoma, NSCLC)
Phase
Phase 2
Status
Active (as of last update)
Company
About BioAtla
BioAtla is pioneering a novel class of therapeutics called Conditionally Active Biologics (CABs), designed to be active only in the specific physiological conditions of diseased tissue, such as the acidic, hypoxic tumor microenvironment. This approach aims to unlock previously undruggable targets and improve the safety and efficacy of cancer therapies. The company has built a robust intellectual property portfolio with over 700 patents and applications and is led by a seasoned team with decades of biotech experience. Its strategy focuses on advancing its internal CAB pipeline while exploring potential partnerships for its platform technology.
View full company profile